Home Clinical Topics FDA approves new first-line treatment for Hodgkin lymphoma

FDA approves new first-line treatment for Hodgkin lymphoma

Author(s):

On March 20, the U.S. Food and Drug Administration (FDA) approved Adcetris (brentuximab vedotin) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy.

Read more via Fda.gov.

LEAVE A REPLY

Please enter your comment!
Please enter your name here